Anika Therapeutics, Inc. 10-Q

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS   Issuer Purchases of Equity Securities   On May 2, 2019, we announced that our Board of Directors approved a $50.0 million share repurchase program with $30.0 million to be utilized for an accelerated share repurchase program, which was completed in January 2020, and $20.0 million reserved for open market repurchases which represents the maximum value of shares that may yet be purchased. No open market repurchases were made during the nine-month period ended September 30, 2022.   ITEM 6. EXHIBITS   Exhibit   No.           3.1 Certificate of Incorporation of Anika Therapeutics, Inc. (incorporated by reference to Exhibit 3.1 to the Current Report on Form 10-K (File No. 001-14027) filed by the Registrant on March 11, 2022)       3.2 Bylaws of Anika Therapeutics, Inc., effective as of June 6, 2018 (incorporated by reference to Exhibit 3.2 to the Current Report on Form 10-K (File No. 001-14027) filed by the Registrant on March 11, 2022)       †10.1 Anika Therapeutics, Inc. 2017 Omnibus Incentive Plan (as amended effective June 8, 2022) (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed (File No. 000-21326) by the Registrant on June 10, 2022)     (31) Rule 13a-14(a)/15d-14(a) Certifications       *31.1 Certification of Dr. Cheryl R. Blanchard, pursuant to Rules 13a-15(e) and 15d-15(e), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.       *31.2 Certification of Michael Levitz, pursuant to Rules 13a-15(e) and 15d-15(e), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.       (32) Section 1350 Certifications       **32.1 Certification of Dr. Cheryl R. Blanchard, and Michael Levitz, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.       (101) XBRL       *101 The following materials from Anika Therapeutics, Inc.’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2022 as filed with the SEC on November 9, 2022, formatted in Inline XBRL (eXtensible Business Reporting Language), as follows:         i. Consolidated Balance Sheets as of September 30, 2022 (unaudited) and December 31, 2021 (unaudited)   ii. Consolidated Statements of Operations and Comprehensive Income for the Three and Nine Months Ended September 30, 2022 and September 30, 2021 (unaudited)   iii. Consolidated Statements of Stockholders’ Equity for the Nine Months Ended September 30, 2022 and September 30, 20201(unaudited)   iv. Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2022 and September 30, 2021 (unaudited)   v. Notes to Consolidated Financial Statements (unaudited)     104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)      * Filed herewith. ** Furnished herewith. † Management contract or compensatory plan or arrangement.     32     SIGNATURES   Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.       ANIKA THERAPEUTICS, INC.         Date: November 9, 2022 By: /s/ MICHAEL LEVITZ       Michael Levitz       Executive Vice President, Chief Financial Officer and Treasurer     (Authorized Officer and Principal Financial Officer)                                                     33